Edwards Lifesciences (EW) Revenue — Quarter Ended Mar 31, 2024
Revenue increased compared with the prior quarter and also rose relative to the same period a year ago. The company cited no specific drivers for the change in its filing context.
Key takeaway
Quarter ended Mar 31, 2024 · FY2024 Q1
Revenue increased compared with the prior quarter and also rose relative to the same period a year ago. The company cited no specific drivers for the change in its filing context.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.3B
Revenue reported for this quarter.
Quarter-over-quarter
+5.0%
Change from the immediately preceding quarter.
Year-over-year
+8.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$5.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2023 | $1.3B | -4.5% |
| Sep 30, 2023 | $1.2B | -8.2% |
| Dec 31, 2023 | $1.3B | +194.6% |
| Mar 31, 2024 | $1.3B | +8.9% |
Revenue performance
Reported revenue moved higher for the quarter, continuing an upward trajectory from the immediately preceding period.
Quarterly comparison
The revenue figure was above both the prior quarter and the same quarter one year earlier. The sequential improvement followed a pattern of quarterly fluctuations seen in earlier periods.
What to watch
With no causal explanation provided in the filing, future revenue direction remains dependent on broader market and operational factors.